How Can Today’s Supply-Chain Challenges Be Fixed?

A DCAT Week program brings together leading Bio/Pharma executives to offer their perspectives on how Bio/Pharma companies and their suppliers are adjusting supply practices now and in the near term.

A DCAT Week program brings together leading Bio/Pharma executives to offer their perspectives on how Bio/Pharma companies and their suppliers are adjusting supply practices now and in the near term. 

Supply-chain challenges and solutions
Longer lead times. Inflationary pressures. Transportation bottlenecks. A changing geopolitical landscape. These are just some of the supply-chain challenges that Bio/Pharma companies and CDMOs/CMOs/suppliers are facing today. But the question is what can be done to address those issues?

The DCAT Week 2022 program, Executive Insights: Navigating the New Supply Chain Paradigm, on Tuesday, March 22, from 9:00 to 10:00 AM, will feature of panel of leading executives to share their perspectives on how the industry is and may further adjust its supply practices today and in the near term.

Participating in the panel to provide perspective on overall supply practices as well as specialized considerations for small-molecule drugs, biologics, and raw materials sourcing are: Christopher Langan, Senior Vice President, API External Manufacturing, Eli Lilly and Company; Bala Sreenivasan, Vice President of Global Supply Chain Operations, Merck & Co., Inc.; and Klaus W. Hagenmueller, Head, Global Supply Chain Management, Health Care Business Line, Evonik Operations GmbH. Derron Stark, Principal, EY-Parthenon, Ernst & Young, will moderate the panel discussion.

The executives will provide practical insights on some of the solutions to address the supply-chain challenges of today and how supply practices between Bio/Pharma companies and CMDOs/CMOs/suppliers have changed and how they will further evolve. They will provide perspectives on further measures for risk mitigation and supply-chain security, additional considerations in contracts, the pros and cons of increasing back integration, and raw materials sourcing strategies, including a discussion on the risk–reward of qualifying second sources and regional alternatives. Additionally, they will discuss how increased digitalization, including the use of artificial intelligence, can be applied to improve resource allocation and outcomes in sourcing and supply-chain functions.

Further information, including how to register for the DCAT Week program, Executive Insights: Navigating the New Supply Chain Paradigm, may be found here.

Recent Feature Articles

CDMOs/CMOs: The Movers and Shakers of 2025

By
As 2025 comes to a close, what were the key developments—expansions and M&A—from CDMOs/CMOs this year? DCAT Value Chain Insights looks at the companies and moves that topped the headlines this year.

EU Policymakers Take Next Step in Key Pharma Reforms

By
The European Commission, the European Parliament, and the Council of the European Union, have agreed to a proposal for the EU’s landmark pharma legislation, setting the stage for major reforms.

2025: The Bio/Pharma Industry’s Year in Review

By
Without question, US-imposed tariffs and ensuing trade deals and the impact on the bio/pharma industry was the number one news story in 2025, going hand-in-hand with US manufacturing investments and drug pricing reforms. What else made the news?

UK, US Strike Agreement for Drug Pricing & Tariffs

By
The UK and the US governments have agreed in principle on drug pricing and tariffs/trade on pharmaceuticals between the two countries, months after the countries formed an initial trade pact. What is the new deal and the impact on pharma?